
1. Infect Dis Clin North Am. 2020 Sep 30. pii: S0891-5520(20)30019-2. doi:
10.1016/j.idc.2020.04.003. [Epub ahead of print]

Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New
Therapeutic Approaches.

Holubar M(1), Meng L(2), Alegria W(2), Deresinski S(3).

Author information: 
(1)Division of Infectious Diseases and Geographic Medicine, Stanford University
School of Medicine, 300 Pasteur Drive, Room L-134, Stanford, CA 94305-5105, USA. 
Electronic address: mholubar@stanford.edu.
(2)Department of Quality, Patient Safety and Effectiveness, Stanford Health Care,
300 Pasteur Drive Lane 134, Stanford, CA 94305, USA.
(3)Division of Infectious Diseases and Geographic Medicine, Stanford University
School of Medicine, 300 Pasteur Drive, Room L-134, Stanford, CA 94305-5105, USA.

Vancomycin and daptomycin are options for the initial treatment of patients with 
methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Treatment options 
for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or
vancomycin-resistant strains include daptomycin, ceftaroline, and combination
therapies. There is a critical need for high-level evidence from clinical trials 
to allow optimally informed decisions in the treatment of MRSA bacteremia.

Copyright Â© 2020 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.idc.2020.04.003 
PMID: 33011050 

